相关实验视频
Updated: Jun 5, 2025

10:29
Generation of Human Chimeric Antigen Receptor Regulatory T Cells
Published on: January 3, 2025
1.2K
关于有效使用T细胞重定向疗法的建议:加拿大共识声明
Guido Lancman1, Kevin Song2, Darrell White3
1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Frontiers in oncology
|December 11, 2024
概括
加拿大专家为多发性骨髓瘤的T细胞重定向疗法制定了指导方针,解决了患者选择,转诊和管理副作用,以更好地实施治疗.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 血液学 血液学 血液学
背景情况:
- 包括双特异性抗体和CAR T细胞在内的T细胞重定向疗法在治疗复发性/耐药性多发性髓瘤方面表现有前途.
- 由于资源需求和协调要求,实施这些先进疗法存在重大挑战.
- 目前,加拿大没有关于有效使用这些新型治疗方法的指导方针.
研究的目的:
- 建立加拿大对多发性骨髓瘤T细胞重定向疗法的共识建议.
- 为优化患者选择,转诊流程和不良事件管理提供指导.
- 支持这些疗法有效地融入加拿大临床实践.
主要方法:
- 通过与加拿大专家和多发性骨髓瘤加拿大代表的三次咨询会议制定的一份共识声明.
- 对临床试验,现实世界的数据和当前文献进行了全面的审查.
- 组建工作组,确定患者选择,转诊途径和不良事件管理的标准.
主要成果:
- 为优化对T细胞重定向疗法患者选择的建议.
- 关于加拿大医疗保健系统中简化转诊途径的指导方针.
- 与这些疗法相关的短期和长期不良事件的管理策略.
结论:
- 这些建议旨在促进加拿大多发性骨髓瘤T细胞重定向疗法的安全和有效实施.
- 这些指南是针对一个多学科的团队,包括医生,护士和药剂师.
- 这一倡议解决了对管理复杂免疫疗法的标准化指导的急需问题,该指导适用于多发性骨髓瘤患者.
相关概念视频
Tumor Immunotherapy
476
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
476
T Cell Activation and Clonal Selection
658
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
658
Cell-mediated Immune Responses
67.0K
Overview
67.0K

